BeOne Medicines Ltd. (HKG:6160)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
155.30
+0.40 (0.26%)
Jun 6, 2025, 3:45 PM HKT

BeOne Medicines Company Description

BeOne Medicines Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally.

The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a monotherapy and in combinations for the treatment of various solid tumors.

Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK‑targeting chimeric degradation activation compound active against wild‑type and mutant BTK; Ociperlimab (BGB-A1217), a TIGIT inhibitor; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC.

It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis.

The company was formerly known as BeiGene, Ltd. and changed its name to BeOne Medicines Ltd. in May 2025.

BeOne Medicines Ltd. was incorporated in 2010 and is based in Basel, Switzerland.

BeOne Medicines Ltd.
BeOne Medicines logo
Country Switzerland
Founded 2010
Industry Biotechnology
Sector Healthcare
Employees 11,000
CEO John Oyler

Contact Details

Address:
Aeschengraben 27
Basel, 4051
Switzerland
Phone 41 61 685 19 00
Website beonemedicines.com

Stock Details

Ticker Symbol 6160
Exchange Hong Kong Stock Exchange
Fiscal Year January - December
Reporting Currency CNY
ISIN Number KYG1146Y1017
SIC Code 2836

Key Executives

Name Position
John V. Oyler Co-Founder, Executive Chairman and Chief Executive Officer
Dr. Xiaobin Wu Ph.D. President, Chief Operating Officer and GM of China
Dr. Xiaodong Wang Ph.D. Co-Chairman of Scientific Advisory Board, Non-Executive Director and Co-Founder
Aaron Rosenberg Chief Financial Officer
Chan Lee General Counsel and Senior Vice President
Wang Lai Ph.D. Global Head of Research & Development
Titus B. Ball Vice President and Chief Accounting Officer
Marcello Damiani Chief Technology Officer
Liza Heapes Head of Investor Relations
Yang Ji Chief Compliance Officer